Original Article Decrease in serum levels of interleukin-1β, interleukin-5 and interleukin-9 after vitamin D repletion in patients with chronic lymphocytic leukemia
Int J Clin Exp Pathol
Vitamin D (VD) deficiency in chronic lymphocytic leukemia (CLL) is associated with a worse prognosis, a shorter time to start the treatment and the overall survival. VD deficiency is the first potentially modi-fiable prognostic factor in CLL that may interfere with the production of cytokines. However, there is the lack of studies concerning the VD repletion and its influence on interleukins in CLL patients. The aim of our prospective study was to assess the influence of cholecalciferol
... ecalciferol repletion on serum interleukins levels in CLL patients. Materials and methods: The study comprised 18 CLL patients. A six-month-long interventional study was conducted in CLL subjects with serum 25-OH-D 3 concentrations at the level of <30 ng/ml. Patients were supplemented with cholecal-ciferol. Interleukins levels were assessed at the beginning of the study and after a six-month-long supplementation of cholecalciferol. Baseline measurements of interleukins were compared to those in apparently healthy controls. Results: CLL patients were characterized by significantly increased levels of IL-1β, IL-4, IL-5, IL-6, IL-9, IL-12, IL-13 and IL-17, in comparison with healthy controls. During the VD supplementation a decrease in IL-1β, IL-1ra, IL-5, IL-9 and IL-17 serum levels was found. The decrease in IL-1β, IL-5 and IL-9 was observed in the subgroup of CLL patients who were not receiving chemotherapy, while in IL-17 in CLL patients on chemotherapy. Conclusion: The VD repletion may exert favorable influence on interleukins levels in VD deficient CLL patients.